Prevention and suppression of experimental allergic encephalomyelitis by an orally active leukocyte recruitment inhibitor, NPC 16570.
An orally active leukocyte recruitment inhibitor, NPC 16570 (N-[9H-fluoren-9-ylethoxycarbonyl]-4-aminobenzoic acid), was evaluated in experimental allergic encephalomyelitis (EAE) in rats. The mean time of disease onset in control animals was 12 +/- 1 days, with peak average clinical scores of 2.5 +/- 0.2, accompanied by perivascular infiltration of inflammatory cells into the CNS. Daily administration (p.o.) of NPC 16570 reduced the clinical severity (by 70%) at 10 and 30 mg/kg, and at 100 mg/kg, no clinical symptoms were detected. When NPC 16570 (100 mg/kg) treatment was initiated 7 days after EAE induction, the severity (75% inhibition) and duration of the disease were attenuated; 2 out of 6 animals showed no overt clinical symptoms and perivascular cell infiltration was prevented, suggesting potential utility in autoimmune diseases.
Lowe
V C
VC
Scios Nova Inc., Baltimore, MD 21224.
Noronha-Blob
L
L
D000284:Administration, Oral; D062365:Aminobenzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D005449:Fluorenes / Q000008:administration & dosage / Q000627:therapeutic use*; D006168:Guinea Pigs; D008297:Male; D051381:Rats; D013116:Spinal Cord / Q000187:drug effects / Q000473:pathology
D062365:Aminobenzoates; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005449:Fluorenes; C085021:N-(9H-fluoren-9-ylethoxycarbonyl)-4-aminobenzoic acid